Remove 2019 Remove Cannabis Remove Data Remove Pharmaceutical
article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

8 Cannabis Trends to Watch in 2019

Cannabis Info

8 Cannabis Trends to Watch in 2019. So, the big marijuana experiment, on a large scale, is opening new opportunities for 2019 but it will be mainly for those huge corporations that have a lot of resources to throw around. Medical research and pharmaceuticals. It will happen in 2019. Recently Aurora spent over $3.5

article thumbnail

NHS To Launch Its First Evidence-Based Cannabis Patient Data Registry This Week – Cannabis Business Executive

SpeedWeed

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. The development has been welcomed and comes as the nation’s doctors are said to be shifting their cultural stance from viewing ‘cannabis as a dirty word’.

Data 52
article thumbnail

Europe Cannabis and Pain Management Devices on Cancer Pain Market – Major Technology Giants in Buzz Again | Cannabis Players:, GW Pharmaceuticals, UNIMED PHARMACEUTICALS, Valeant Pharmaceuticals, Insys Therapeutics

Cannabis Law Report

Europe Cannabis and Pain Management Devices on Cancer Pain Market Report 2019 is dispensed after a thorough study of various key market segments such as market size, latest trends, market threats and key drivers driving the Europe Cannabis and Pain Management Devices on Cancer Pain market. UNIMED PHARMACEUTICALS.

article thumbnail

BBC Report: EU Approves , “Epidyolex” GW Pharmaceuticals

Cannabis Law Report

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. Medical cannabis costs family £4,000 a month to help teenager. What is Epidyolex?

article thumbnail

MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.